account_balance
Investment manager · 13F filer · SEC CIK 1816307
Silverarc Capital Management, LLC
Reported value$899Mas of Jun 30, 2026
Positions65 20 new, 22 sold out
Top 10 weight45.3%ASND alone is 6%
FiledAug 1344 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ASNDAscendis Pharma A/s
6.1%New
CELCCelcuity Inc
5.8%Added +40%
COGTCogent Biosciences Inc
5.5%Trimmed −3%
URGNUrogen Pharma Ltd
5.3%Trimmed −13%
IMNMImmunome Inc
4.8%Added +9%
DNTHDianthus Therapeutics Inc
4.2%Trimmed −40%
RYTMRhythm Pharmaceuticals Inc
3.8%
ORKAOruka Therapeutics Inc
3.7%Added +134%
GLUEMonte Rosa Therapeutics Inc
3.0%Trimmed −45%
SNDXSyndax Pharmaceuticals Inc
3.0%Added +37%
ELVNEnliven Therapeutics Inc
2.8%New
IMVT2.7%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ASND Ascendis Pharma A/s 6.1% NewCELC Celcuity Inc 5.8% Added +40%COGT Cogent Biosciences Inc 5.5% Trimmed −3%URGN Urogen Pharma Ltd 5.3% Trimmed −13%IMNM Immunome Inc 4.8% Added +9%DNTH Dianthus Therapeutics Inc 4.2% Trimmed −40%RYTM Rhythm Pharmaceuticals Inc 3.8% HeldORKA Oruka Therapeutics Inc 3.7% Added +134%GLUE Monte Rosa Therapeutics Inc 3.0% Trimmed −45%SNDX Syndax Pharmaceuticals Inc 3.0% Added +37%ELVN Enliven Therapeutics Inc 2.8% NewIMVT Immunovant Inc 2.7% Added +49%
What changed
Biggest moves since Mar 31, 2026
remove_circleSold out
- Kalvista Pharmaceuticals Inc $57.9M
- NUVL $36.4M
- Ascendis Pharma A/s $28.5M
- Centessa Pharmaceuticals PLC $18.5M